One of the primary challenges in the regulatory affairs of the pharmaceutical industry is keeping pace with the ever-evolving regulatory landscape.

With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in ...

Sanofi's Chief Digital Officer Emmanuel Frenehard had a thought that he just couldn't shake: how can Sanofi extend the ...

TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ: MDCX TSXV: MDCX) (the “Company”) is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical ...

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...